Core Viewpoint - The China Tong Ren Tang Group hosted the third Traditional Chinese Medicine Conference, showcasing its commitment to innovation and high-quality development in traditional Chinese medicine through a comprehensive display of products and research achievements [1] Product Matrix Presentation - Tong Ren Tang Technology Company presented over twenty major products, including Xihuang Pills, Jingzhi Niuhuang Jiedu Tablets, Liuwei Dihuang Pills, and others, covering categories such as anti-cancer, tonics, kidney diseases, and detoxification [3] - The company has developed a "six-dimensional product matrix" around its more than 200 traditional Chinese medicine products, ensuring that each product meets specific consumer needs [5] Rich Product Categories - The diverse range of health products, including Ejiao honey dates, herbal essence masks, and weight loss teas, attracted significant attention from medical professionals and researchers [5] - The company emphasizes the integration of traditional techniques with modern innovation, showcasing its commitment to quality and consumer health [5] Attention to Processing Techniques - The "intangible cultural heritage" exhibition highlighted the company's traditional processing techniques, which enhance the efficacy and adaptability of traditional Chinese medicine [6][8] - The processing methods, such as the treatment of herbs to improve absorption and reduce adverse effects, were demonstrated, showcasing the company's dedication to maintaining the integrity of traditional practices [10] Research and Innovation Driving Development - The company presented solid laboratory data on major products at the conference, enhancing consumer and client understanding of product efficacy [11] - Ongoing research includes clinical studies on various traditional Chinese medicine products, providing a scientific basis for their clinical applications [11]

Core Viewpoint - The article highlights the significant growth and market dominance of Suhexiang Wan, a traditional Chinese medicine, in the cardiovascular disease prevention and treatment sector, driven by policy support and modern clinical research [2][3]. Group 1: Market Performance - Suhexiang Wan's sales in urban public hospitals increased from 42.08 million yuan in 2020 to 558 million yuan in 2023, while retail sales in urban pharmacies rose from 232,000 yuan to 8.2 million yuan by 2024 [1]. - In the first half of 2024, Lei Yun Shang's Suhexiang Wan held a market share of approximately 75.15% in urban public medical institutions, with a retail growth rate of 236%, significantly outpacing competitors like Pian Zai Huang and Gui Ling Ji [1][3]. Group 2: Clinical and Retail Insights - Suhexiang Wan has been widely applied in clinical settings, covering nearly 3,000 hospitals and demonstrating effectiveness in emergency cases and cardiovascular disease prevention [4]. - The product's clear efficacy and modern adaptation have contributed to its retail success, contrasting with the slower growth of other traditional medicines like An Gong Niu Huang Wan and Gui Ling Ji, which saw declines in sales [5][6]. Group 3: Policy and Industry Trends - The Chinese government has intensified support for traditional Chinese medicine, with the "14th Five-Year Plan for Traditional Chinese Medicine Development" emphasizing the development and clinical application of classic formulas like Suhexiang Wan [6]. - The demand for cardiovascular health products is surging, with 81.7% of respondents in a health survey willing to invest more in health, indicating a growing market for traditional Chinese medicine [6][7]. Group 4: Competitive Landscape - The market for cardiovascular traditional Chinese medicine has expanded significantly, with total sales increasing from 5.216 billion yuan in 2017 to 10.083 billion yuan in 2024, nearly doubling [3]. - Suhexiang Wan's competitive edge is reinforced by its strong clinical evidence and market positioning, as it continues to capture a larger share of the growing demand for cardiovascular treatments [8].